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Insulin-like growth factor 1 (IGF1) is involved in the proliferation of mouse and rat endometrial cells 
in a paracrine or autocrine manner. Insulin-like growth factor binding protein-3 (IGFBP3) modulates 
actions of IGFs directly or indirectly. The present study aimed to determine whether IGFBP3 is 
involved in the regulation of proliferation of mouse endometrial cells. Mouse endometrial epithelial 
cells and stromal cells were isolated, and cultured in a serum free medium. IGF1 stimulated DNA 
synthesis by endometrial epithelial and stromal cells, and IGFBP3 inhibited IGF1-induced DNA syn-
thesis. Estradiol-17β (E2) decreased the Igfbp3 mRNA level in endometrial stromal cells, whereas 
it increased the Igf1 mRNA level. Transforming growth factor α (TGFα) significantly decreased 
IGFBP3 expression at both the mRNA and secreted protein levels in endometrial stromal cells. 
Progesterone (P4) did not affect the E2-induced down-regulation of Igfbp3 mRNA expression in 
endometrial stromal cells, although P4 alone increased Igfbp3 mRNA levels. The present findings 
suggest that in mouse endometrial stromal cells E2 enhances IGF1 action through enhancement 
of IGF1 synthesis and reduction of IGFBP3 synthesis, and that TGFα affects IGF1 actions through 
modulation of IGFBP3 levels.
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INTRODUCTION
The mammalian endometrium consists of epithelial and 
stromal cells. The proliferation of endometrial cells varies 
with cyclic changes of ovarian steroid hormone levels during 
the estrous cycle, and is controlled by ovarian steroid hor-
mones. Estrogen stimulates the proliferation of endometrial 
epithelial cells, while simultaneous treatment with estrogen 
and progestin stimulates the proliferation of uterine stromal 
cells in adult mice (Huet-Hudson et al., 1989). The steroid 
hormone-induced proliferation of endometrial cells is 
thought to be mediated by growth factors produced in endo-
metrial stromal cells (Tomooka et al., 1986; DiAugustine et 
al., 1988; Beck and Garner, 1992; Das et al., 1994; Cooke 
et al., 1997). Insulin-like growth factor 1 (IGF1) is expressed 
in all components of the mouse uterus and its expression is 
regulated by estrogen (Murphy et al., 1987; Ghahary et al., 
1990; Kapur et al., 1992; Ohtsuki et al., 2007). Moreover, 
IGF1 promotes the proliferation of endometrial cells (Shiraga 
et al., 1997; Sato et al., 2002; Inoue et al., 2005; Zhu et al., 
2007). These findings suggest that IGF1 is one of factors 
involved in the regulation of endometrial cell proliferation.
The insulin-like growth factor binding protein (IGFBP) 
family is composed of six subtypes, of which IGFBP3 is 
known to be the most abundantly expressed in many tis-
sues. IGFBP3 modulates actions of IGF1 by forming an 
IGF1-IGFBP3 complex, resulting in the blockage of IGF1 
actions or the prolongation of the half-life of IGF1 (Hwa et 
al., 1999; Duan and Xu, 2005). IGFBP3 also directly inhib-
ited cell proliferation by binding to an IGFBP3 receptor in an 
IGF-independent signaling pathway (Mochizuki et al., 2006). 
Thus, IGFBP3 is likely to modulate actions of IGFs directly 
and indirectly in various tissues. The IGFBP3 receptor has 
been identified as a low-density lipoprotein receptor-related 
protein 1 (LRP1), which is also called transforming growth 
factor-β receptor type V (Leal et al., 1997; Danielpour and 
Song, 2006). Lrp1 mRNA expression in the mouse uterus 
was studied to clarify the involvement of IGFBP3 receptors 
on the regulation of IGFBP3 actions within the endometrium.
IGFBP3 is expressed in the mouse uterus, and expres-
sion levels change during estrous cycle (Girvigian et al., 
1994; Molnar and Murphy, 1994; Tang et al., 1994). These 
findings suggest that uterine IGFBP3 production is partly 
regulated by ovarian steroid hormones. The present study 
was aimed at clarifying the role of IGFBP3 in the prolifera-
tion of endometrial cells and the effect of estradiol-17β  (E2) 
on IGFBP3 production in endometrial cells. Primary cultures 
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of mouse endometrial epithelial and stromal cells were used 
in the present study.
In recent studies, epidermal growth factor (EGF) sup-
pressed IGFBP3 expression in human cervical epithelial 
cells and esophageal epithelial cells (Hembree et al., 1994; 
Takaoka et al., 2006). Furthermore, excess expression of 
heparin-binding epidermal growth factor (HB-EGF) lowered 
IGFBP3 expression (Provenzano et al., 2005). These find-
ings suggest that the production of IGFBP3 is partly regu-
lated by members of the EGF family. Transforming growth 
factor α (TGFα), a member of the EGF family, is detected in 
the mouse uterus during the peri-implantation period 
(Tamada et al., 1991). In addition, TGFα expression is reg-
ulated by estrogen (Nelson et al., 1992). These observations 
led to the idea that TGFα is involved in the regulation of 
IGFBP3 expression in the mouse uterus. In the present 
study, we investigated the effect of TGFα on IGFBP3 
expression in endometrial cells.
MATERIALS AND METHODS
Animals
Immature (21 to 23 days old) and adult (8 weeks old) female 
mice of the ICR strain were used in the present study. They were 
housed in a temperature-controlled animal room and were fed a 
commercial diet of CA-1 (CLEA Japan, Osaka) and tap water. All 
animal care and experiments were conducted in accordance with 
the Guidelines for Animal Experimentation of Okayama University, 
Japan.
Cell culture
Uterine epithelial and stromal cells were isolated according to 
methods used in previous studies (Ross et al., 1993; Shiraga et al., 
1997; Komatsu et al., 2003). Isolated uterine epithelial cells were 
seeded on collagen-coated culture wells at a density of about 5×104
cells/cm2. Isolated stromal cells separated from epithelial cells were 
seeded on poly-L-lysine coated culture wells at a density of about 
6×104 cells/cm2. Stromal cells were first cultured in a 1:1 mixture of 
Dulbecco’s modified Eagle’s medium and Ham’s F-12 medium with-
out phenol red (DME/F12, Sigma Aldrich, St. Louis, MO, USA) con-
taining 2% dextran-coated charcoal-treated fetal bovine serum. After 
a 1 day pre-culture, the cells were cultured in serum-free DME/F12 
supplemented with BSA (1 g/l), hydrocortisone (100 μg/l), triiodothy-
ronine (400 ng/l), transferrin (10 mg/l), glucagon (10 ng/l), parathor-
mone (200 ng/l), sodium selenite (5 μg/l), and insulin (100 μg/l). The 
plates were incubated at 37°C in an atmosphere of 5% CO2, and 
the medium was changed every 2 days.
E2 and progesterone (P4) (Sigma-Aldrich) were initially dis-
solved in ethanol to yield 10 μM stock solutions (0.03% and 0.01% 
ethanol, respectively). Working solutions of E2 and P4 were made 
by diluting the stock solutions with culture medium. AG1478 (Biomol 
International, Plymouth Meeting, PA, USA) was initially dissolved in 
dimethyl sulfoxide (DMSO) (10 μM; 0.01% DMSO) and later diluted 
with culture medium.
Determination of DNA synthesis
DNA synthesis was assayed by immunochemical detection of 
5’-bromo-2’-deoxyuridine (BrdU) incorporation into the cell nucleus 
by using a Cell Proliferation ELISA, BrdU Kit (Roche Diagnostics, 
Mannheim, Germany). Cultured cells were treated with 100 ng/ml 
recombinant human IGF1 (Amersham Pharmacia Biotech, Uppsala, 
Sweden) with or without recombinant mouse IGFBP3 (R&D Systems,
Minneapolis, MN, USA) for 16 or 48 hr. These cells were exposed 
to 100 μM BrdU for the last 4 hr. The cells were then fixed and incu-
bated with a peroxidase-conjugated anti-BrdU monoclonal antibody 
from mouse-mouse hybrid cells (Anti-BrdU-POD). After washing, 
tetramethyl-benzidine was added as a substrate. The peroxidase 
reaction was stopped with 0.2 M sulfuric acid, and the absorbance 
at 450 nm was measured with a micro-plate reader (Bio-Rad, 
Hercules, CA, USA).
cDNA synthesis and PCR amplification
Total RNA was prepared from cultured endometrial cells and 
the whole uterus by using a single-step method (Chomczynski and 
Sacchi, 1987), and was transcribed by using Thermoscript Reverse 
Transcriptase (Invitrogen, CA, USA) according to the manufac-
turer’s instructions. Primers purchased from Invitrogen are listed in 
Table 1. PCR was performed with Takara Taq (Takara Bio, Otsu, 
Japan) and a Gene Amp PCR System 9700 thermal cycler (Applied 
Biosystems, Branchburg, NJ, USA). PCR conditions were: 20 sec 
at 94°C; an appropriate number of cycles of 94°C for 30 sec, 60°C 
for 30 sec, and 72°C for 30 sec; and 10 min at 72°C. A 10-μl aliquot 
of each reaction was electrophoresed on 2% agarose gel, stained 
with ethidium bromide, and photographed under ultraviolet rays. 
Signal intensities were measured with the Kodak 1D Imaging 
System (Eastman Kodak, CT, USA). The amount of each target 
mRNA was normalized to the amount of ribosomal protein L19 
(Rpl19) mRNA.
Western blot analysis of IGFBP3
Culture media (400 μl) were concentrated by lyophilization. The 
concentrated media were subjected to 12.5% SDS-PAGE and 
transferred to nitrocellulose membrane (Schleicher & Schuell, 
Keene, NH, USA). The membranes were blocked for 1 hr with 1% 
bovine serum albumin (BSA) dissolved in Tris-buffered saline con-
taining 0.1% Tween-20, and were then incubated sequentially with 
goat anti-mouse IGFBP3 antibody (1:1,000, R&D Systems, MN, 
USA) and horseradish peroxidase conjugated anti-goat secondary 
antibody (1:5,000, Santa Cruz Biotechnology, CA, USA). Peroxi-
dase activity was detected by using luminol (Sigma Aldrich) and a 
hydrogen peroxide reaction. Recombinant mouse IGFBP3 (R&D 
Systems) was used as a positive control.
Statistical analysis
Data were expressed as the mean±SEM. Differences among 
groups were analyzed by analysis of variance followed by Tukey’s 
test.
Table 1. Sequences of primers used in RT-PCR.
Name Sequence Length (bp)
Igf1
Forward GTCGTCTTCACACCTCTTCTACCT 135
Reverse TAAAAGCCCCTCGGTCCACACAC
Igf1r
Forward TTCTTCTATGTCCCCGCCAAA 354
Reverse AGCCTCGTTTACCGTCTTGAT
Igfbp3
Forward TAAGCACCTACCTCCCCTCCCAACCT 346
Reverse TTTGGGATGTGGACGCCTCTGGGACT
Lrp1
Forward GGGGACAATGACTGCCAAGAC 415
Reverse CATCACACTCTTCCTTGGGCT
Tgfa
Forward AGCCAGAAGAAGCAAGCCATCACT 502
Reverse CTCATTCTCGGTGTGGGTTAGCAA
Rpl19
Forward GAAATCGCCAATGCCAACTC 406
Reverse TCTTAGACCTGCGAGCCTCA
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RESULTS
Igfbp3, Igf1, and Igf1r mRNA levels in the mouse uterus 
during the estrous cycle
Igfbp3, Igf1, and Igf1r mRNA levels in the mouse uterus 
were analyzed at 24-hr intervals during the estrous cycle by 
using semi-quantitative RT-PCR. Igfbp3 and Igf1r mRNA 
levels were highest at diestrus 1 during the 4-day estrous 
cycle. In contrast, Igf1 mRNA levels were highest at 
proestrus (Fig. 1).  
IGFBP3 inhibited IGF1-induced DNA synthesis in endo-
metrial cells
Endometrial epithelial and stromal cells were treated with 
recombinant mouse IGFBP3 with or without IGF1 (100 ng/ml)
to study effect of IGFBP3 on DNA synthesis. Based on a 
preliminary study, we measured DNA synthesis by detecting 
BrdU uptake 48 hr after IGF1/IGFBP3 treatment in endome-
trial epithelial cells, or 16 hr in stromal cells (Shiraga et al., 
1997; Inoue et al., 2005). IGF1 stimulated DNA synthesis in 
both endometrial epithelial and stromal cells, and IGFBP3 
inhibited this stimulatory effect of IGF1 in a dose-dependent 
manner (Fig. 2).
E2 and TGFα suppressed IGFBP3 expression in endo-
metrial stromal cells
Igf1, Igfbp3, Igf1r, and Lrp1 mRNA levels in endometrial 
stromal cells were analyzed by using semi-quantitative RT-
PCR. E2 treatment increased Igf1 mRNA levels after 24 hr, 
whereas Igfbp3 mRNA levels decreased. E2 had no effect 
on Lrp1 or Igf1r mRNA levels (Fig. 3).
The effect of TGFα on Igfbp3 mRNA levels in endome-
trial cells were studied, because Tgfa and Egfr mRNAs are 
both expressed in mouse endometrial cells, and EGF family 
growth factors are involved in IGFBP3 production in various 
tissues and cells. E2 significantly stimulated Tgfa mRNA 
expression in endometrial stromal cells (Fig. 4A). In endo-
metrial stromal cells, TGFα reduced Igfbp3 mRNA expres-
sion in a dose-dependent manner, but did not affect Lrp1
mRNA levels (Fig. 4B).
Endometrial stromal cells were treated with E2 or TGFα,
and the cellular Igfbp3 mRNA levels (Fig. 5A) and IGFBP3 
protein levels in the culture media were analyzed by western 
blotting (Fig. 5B). Recombinant mouse IGFBP3 was used as 
a positive control, and two immunoreactive bands of 35 kDa 
Fig. 1. Expression of Igfbp3, Igf1, and Igf1r mRNA in the uterus 
during the estrous cycle. Uteri were obtained from adult female mice 
at each stage of the estrous cycle. The upper panel shows ethidium 
bromide-stained electrophoretic patterns of PCR products. Band 
intensities were measured, and normalized according to the Rpl19
mRNA levels. L, 100-bp DNA ladder; P, proestrus; E, estrus; D1, 1st 
day of diestrus; D2, 2nd day of diestrus. In the histograms, each col-
umn represents a mean±SEM. The data are shown as relative val-
ues compared to that at proestrus. The number in each column 
indicates the number mice used. *, p<0.01; **, p<0.05, significantly 
different between stages of the estrous cycle.
Fig. 2. Effect of IGFBP3 on DNA synthesis in cultured endometrial 
cells. Endometrial cells were treated with IGFBP3 (0, 10, 100 mM) in 
the presence (100 ng/ml) or absence of IGF1 for 48 hr (epithelial 
cells) or 16 hr (stromal cells). BrdU (100 μM) was added for the last 
4 hr of IGF1 treatment. BrdU incorporation into the nucleus was 
analyzed as DNA synthesis. Each column represents the 
mean±SEM of triplicate wells. Experiments were replicated three 
times. a, p<0.05, significantly different from corresponding control 
(–IGF1); b, p<0.05, significantly different from corresponding IGF1-
treated group (+IGF1).
Fig. 3. Effect of E2 on Igf1, Igfbp3, Igf1r, and Lrp1 mRNA expres-
sion in endometrial stromal cells. Igf1, Igfbp3, Igf1r, and Lrp1
mRNA levels were analyzed by semi-quantitative RT-PCR. Endo-
metrial stromal cells were treated with E2 (0, 10–10, 10–9, 10–8 M) for 
24 hr. Each column represents the mean±SEM of triplicate wells. 
Experiments were replicated three times. L, 100-bp DNA ladder; *, 
p<0.05, significantly different from control.
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and 40 kDa were detected. In the culture media of endome-
trial stromal cells, two immunoreactive bands were also 
detected (37 and 42 kDa). After 48 hr, both E2 and TGFα
decreased the Igfbp3 mRNA and secreted IGFBP3 protein 
levels.
AG1478 inhibited the TGFα effect on Igfbp3 mRNA 
expression, but not the effect of E2
Endometrial stromal cells were treated with AG1478, an 
inhibitor of the tyrosine kinase of the EGFR, in the presence 
of TGFα or E2, to examine the TGFα signaling pathway 
involving EGFR. AG1478 nullified the inhibitory effect of 
TGFα on Igfbp3 mRNA expression, but did not restore the 
E2-induced suppression of Igfbp3 mRNA expression (Fig. 6).
Igfbp3 mRNA expression was not decreased by E2 or 
TGFα in endometrial epithelial cells
Endometrial epithelial cells were treated with E2 or 
TGFα, and their cellular Igfbp3 mRNA levels were analyzed 
after 24 hr. E2 increased Igfbp3 mRNA in a dose-dependent 
Fig. 4. Tgfa mRNA expression, and effects of TGFα on Igfbp3 and 
Lrp1 mRNA expression in endometrial stromal cells. (A) The effect 
of E2 on Tgfa mRNA expression was analyzed by semi-quantitative 
RT-PCR. Endometrial stromal cells were treated with E2 (0, 10–10, 
10–9, 10–8 M) for 24 hr. Each column represents the mean±SEM of 
triplicate wells. Experiments were replicated three times. *, p<0.05, 
significantly different from corresponding control; L, 100-bp DNA 
ladder. (B) The effect of TGFα on Igfbp3 and Lrp1 mRNA expres-
sions was analyzed by semi-quantitative RT-PCR. Endometrial 
stromal cells were treated with TGFα (0, 0.1, 1, 10, 20 ng/ml) for 24 
hr. Each column represents the mean±SEM of triplicate wells. 
Experiments were replicated three times. *, p<0.05, significantly dif-
ferent from corresponding control.
Fig. 5. Effects of E2 and TGFα on Igfbp3 mRNA and IGFBP3 
expression in endometrial stromal cells. Endometrial stromal cells 
were treated with E2 (10–9 M) or TGFα (10 ng/ml). At 48 hr, condi-
tioned media (400 μl) were harvested and lyophilized. (A) Igfbp3
mRNA levels were analyzed by semi-quantitative RT-PCR. L, 100-
bp DNA ladder. Each column represents the mean±SEM of triplicate 
wells. Experiments were replicated three times. *, p<0.05, signifi-
cantly different from control. (B) IGFBP3 expression was analyzed 
by western blotting using anti-mouse IGFBP3 antibody. Extracts of 
concentrated media of endometrial stromal cells (400 μl) and 
rmIGFBP3 (15 ng) were subjected to SDS-PAGE in a 12.5% gel 
under reducing conditions; rmIGFBP3 served as a positive control. 
The positions of molecular weight markers are shown on the left.
Fig. 6. Effect of AG1478 on Igfbp3 mRNA expression in endometrial 
stromal cells. Endometrial stromal cells were treated with AG1478 
(10–6 M) in the presence of E2 (10–9 M) or TGFα (10 ng/ml) for 24 hr. 
Igfbp3 mRNA levels were analyzed by semi-quantitative RT-PCR. 
Each column represents the mean±SEM of triplicate wells. Experi-
ments were replicated three times. L, 100-bp DNA ladder; *, p<0.05, 
significantly different from corresponding control of vehicle (DMSO) 
treatment; #, p<0.05, significantly different from DMSO treatment.
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manner (Fig. 7A), but TGFα had no effect on Igfbp3 mRNA 
expression (Fig. 7B).
P4 increased Igfbp3 mRNA levels in endometrial stromal 
cells, but not in endometrial epithelial cells
Endometrial epithelial and stromal cells were treated 
with E2 (10–9 M) and/or P4 (10–7 M), and harvested 24 hr 
after the treatment to study the involvement of P4 in Igfbp3
mRNA expression. In endometrial epithelial cells, P4 
increased Igfbp3 and Igf1r mRNA levels in the presence of 
E2, and E2 alone increased Igfbp3 mRNA levels, as already 
shown (Fig. 8A). In endometrial stromal cells, P4 increased 
Igfbp3 mRNA levels. E2 increased Igf1 mRNA levels and 
decreased Igfbp3 mRNA levels, but P4 did not nullify the 
E2-induced decrease in Igfbp3 mRNA levels (Fig. 8B).
DISCUSSION
IGFBPs are known to modulate actions of IGF1 and 
IGF2 in various tissues, and IGFBP3 has been widely 
shown to inhibit cell proliferation (Huynh et al., 2002; Mishra 
and Murphy, 2004; Strange et al., 2004; Duan and Xu, 
2005). The present study demonstrated, for the first time, 
that IGFBP3 exerts an inhibitory effect on the proliferation of 
mouse endometrial cells in the presence of IGF1. IGF1 stim-
ulates DNA synthesis in endometrial epithelial and stromal 
cells (Shiraga et al., 1997; Sato et al., 2002; Inoue et al., 
2005; Zhu et al., 2007). IGFBP3 treatment nullified this stim-
ulatory effect of IGF1 on endometrial cells, but IGFBP3 
alone did not affect DNA synthesis in endometrial stromal 
cells. Although the binding of IGFBP3 to IGF1 in our culture 
system for mouse endometrial cells was not ascertained in 
the present study, IGFBP3 released from endometrial cells 
probably modulates IGF1 actions in an autocrine or para-
crine manner.
The anti-proliferative effects of IGFBPs, including 
IGFBP3, occur through IGF-independent mechanisms as 
well as IGF-dependent ones (Huang et al., 2003; Cavaille et 
al., 2006; Mochizuki et al., 2006). Lrp1 mRNA was detected 
in endometrial epithelial and stromal cells, but IGFBP3 alone 
did not affect DNA synthesis in the endometrial cells. These 
results suggest that the IGF-independent anti-proliferative 
action of IGFBP3 did not function, at least in our culture sys-
tem for mouse endometrial cells. It is not clear what actions 
of IGFBP3 are regulated through Lrp1, the IGFBP3 receptor 
expressed in endometrial cells.
E2 decreased IGFBP3 expression in endometrial 
stromal cells, which is consistent with previous studies of 
uteri in several species (Molnar and Murphy, 1994; 
Fig. 7. Effects of (A) Estradiol-17β (E2) and (B) TGFα on Igfbp3
mRNA expression in endometrial epithelial cells. Endometrial epi-
thelial cells were treated with E2 (0, 10–10, 10–9, 10–8 M) or TGFα (0, 
0.1, 1, 10, 20 ng/ml) for 24 hr. Igfbp3 mRNA levels were analyzed 
by semi-quantitative RT-PCR. Each column represents the 
mean±SEM of triplicate wells. Experiments were replicated three 
times. L, 100-bp DNA ladder; *, p<0.05, significantly different from 
control.
Fig. 8. Effects of E2 and/or P4 on Igf1, Igfbp3, and Igf1r mRNA 
expression in endometrial cells. Endometrial epithelial cells (A) and 
stromal cells (B) were treated with E2 (10–9 M) and/or P4 (10–7 M) 
for 24 hr Igf1, Igfbp3, and Igf1r mRNA levels were analyzed by 
semi-quantitative RT-PCR. Each column represents the mean±SEM 
of triplicate wells. Experiments were replicated three times. L, 100-
bp DNA ladder; *, p<0.05, significantly different from control.
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Kleinman et al., 1995; Liu et al., 1997; Peterson et al., 
1998). The E2-induced decrease in Igfbp3 mRNA levels 
was inhibited by pure antiestrogen ICI182,780 (data not 
shown). The mechanism by which estrogen regulates Igfbp3 
expression is not clear. The promoter of rat Igfbp3 has been 
characterized, and contains two contiguous sequences 
showing 80% similarity with the consensus estrogen 
response element (ERE) (Albiston et al., 1995). The 5’-
flanking region of mouse Igfbp3, the putative promoter, also 
contains an ERE-like sequence. Functional analysis of the 
promoter of mouse Igfbp3 is needed.
Igf1 mRNA levels changed during the estrous cycle, 
which was consistent with our previous report (Ohtsuki et 
al., 2007). Estrogen stimulates Igf1 transcription (Murphy et 
al., 1987; Ghahary et al., 1990; Kapur et al., 1992; Zhou et 
al., 1994; Ohtsuki et al., 2005), and high levels of circulating 
estrogen at proestrus induced high Igf1 mRNA levels. Igf1r 
mRNA levels also changed during the estrous cycle; they 
were high at diestrus and low during proestrus and estrus, 
suggesting that the responsiveness of endometrial cells to 
IGF1 depends upon the stage of the estrous cycle, and pos-
sibly upon levels of estrogen and progestin. Since estrogen 
induced Igf1r mRNA expression only in endometrial epithe-
lial cells, Igf1r mRNA expression may be regulated in tissue-
specific manner.
Igfbp3 mRNA levels were highest at diestrus and low 
during proestrus and estrus. This reduction in Igfbp3 mRNA 
levels may have been caused by high circulating estrogen 
levels, since estrogen decreased Igfbp3 mRNA levels in 
endometrial stromal cells. Importantly, the change in Igfbp3
mRNA levels during the estrous cycle was in a pattern oppo-
site to that of Igf1 mRNA expression. IGF1 is regarded as 
one of the growth factors controlling the estrogen-induced 
proliferation of endometrial cells. IGF1 has been shown to 
stimulate DNA replication in both endometrial epithelial and 
stromal cells (Shiraga et al., 1997; Inoue et al., 2005). In the 
present study, the mitogenic action of IGF1 was depressed 
by high levels of IGFBP3. Therefore, estrogen probably 
stimulates IGF1 action in the mouse endometrium by stimu-
lating Igf1 transcription and inhibiting Igfbp3 transcription. 
The correlation between the expression of Igf1 and Igfbp3
and the proliferation of endometrial cells during the estrous 
cycle remains to be studied.
Progestin is essential for the initiation of the cell cycle in 
endometrial stromal cells. P4 stimulates the proliferation of 
endometrial stromal cells in the presence of estrogen 
(Komatsu et al., 2003), although estrogen alone does not 
stimulate proliferation (Quarmby and Korach, 1984). P4 
alone increased Igfbp3 mRNA expression in endometrial 
stromal cells, while P4 had no effect on Igfbp3 mRNA 
expression in endometrial epithelial cells. Furthermore, P4 
did not affect the E2-induced down-regulation of IGFBP3 
expression. These findings correspond well to in-vivo data 
showing that Igfbp3 mRNA levels are high at diestrus 1 and 
2, during which circulating levels of P4 are also high (Smith 
et al., 1975). Circulating levels of estrogen and progestin are 
higher at estrus. High levels of estrogen will reduce the 
effect of progestin on IGFBP3 expression. However, circu-
lating levels of estrogen decrease from proestrus, and 
progestin is dominant during late estrus and diestrus. There-
fore, progestin stimulates IGFBP3 production from endome-
trial stromal cells at diestrus.
Igfbp3 mRNA was detected by in situ hybridization in 
the endometrial stromal cells juxtaposed to endometrial epi-
thelial cells in the rat uterus, but was not detected in the 
endometrial epithelial cells (Girvigian et al., 1994). Igfbp4
mRNA was detected in endometrial luminal epithelial cells. 
Interestingly, estrogen increased Igfbp3 mRNA expression 
in endometrial epithelial cells, indicating that estrogen differ-
entially regulates Igfbp3 transcription in a tissue-specific 
manner.
The roles of IGFBP3, produced in endometrial epithelial 
cells, are not clear. The proliferation of endometrial epithelial 
cells was mainly regulated by growth factors produced in 
endometrial stromal cells, and levels of IGFBP3 secreted 
from endometrial epithelial cells may be low compared to 
those of endometrial stromal cells, even if estrogen stimu-
lated Igfbp3 transcription in the epithelial cells. Hence, epi-
thelial IGFBP3 may not be involved in the estrogen-induced 
proliferation of endometrial epithelial cells.
We previously showed that TGFα acts as a mitogenic 
factor in endometrial stromal cells (Komatsu et al., 2003). In 
the present study, we demonstrated for the first time that 
TGFα decreases IGFBP3 expression in mouse endometrial 
stromal cells. Members of the EGF family, such as EGF and 
HB-EGF, have been shown to reduce IGFBP3 expression in 
various cell types (Hembree et al., 1994; Wraight and 
Werther, 1995; Provenzano et al., 2005; Takaoka et al., 
2006). In contrast, TGFα stimulates IGFBP3 synthesis in 
human mammary epithelial cells (Sivaprasad et al., 2004). 
Thus, TGFα exhibits opposite effects on the modulation of 
IGFBP3 expression, according to cell type.
In mouse endometrial stromal cells, TGFα induced inhi-
bition of Igfbp3 mRNA expression by way of EGFR signal-
ing, because AG1478 blocked TGFα inhibition of Igbp3
mRNA expression. In contrast, the E2-induced decrease in 
Igfbp3 mRNA levels in endometrial stromal cells was not 
recovered by AG1478, indicating that EGFR signaling was 
not involved in E2 inhibition of Igfbp3 mRNA expression, 
although E2 stimulated TGFα expression. These results 
suggest that E2 and TGFα act separately on Igfbp3 expres-
sion.
The proliferation of endometrial cells is regulated by 
growth factors, including IGF1 produced in endometrial 
stromal cells (Bigsby and Cunha, 1986; Astrahantseff and 
Morris, 1994; Cooke et al., 1997; Pierro et al., 2001). IGF1 
expression and IGFBP3 expression were conversely regu-
lated by estrogen in endometrial stromal cells. Up-regulation 
of IGF1 expression and down-regulation of IGFBP3 expres-
sion by estrogen in the endometrial stromal cells was dem-
onstrated, which suggests that estrogen enhances IGF1 
action through the reduction of IGFBP3 expression at the 
transcription level. TGFα, whose production was stimulated 
by estrogen, decreased IGFBP3 production at the level of 
transcription, resulting in the enhancement of IGF1 action. 
These results suggest that estrogen suppresses IGFBP3 
production in multiple ways, and stimulates the proliferation 
of endometrial cells through the enhancement of IGF1 
action.
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